Translational Neuroimmunology

Brain tumors are characterized by profound local and systemic immune alterations that critically shape disease progression and therapeutic responses. In high-grade gliomas and brain metastases, the tumor microenvironment is dominated by immunosuppressive myeloid cells, including monocyte-derived macrophages and microglia. Deciphering the complex interplay between these myeloid populations, tumor cells, and other immune cells is essential for the development of effective immunotherapies.

Our research group investigates immune dysregulation in neurosurgical diseases, with a particular focus on the myeloid compartment. We study how tissue-resident and infiltrating immune cells contribute to disease pathophysiology in primary and metastatic brain tumors, as well as in other neurosurgical conditions. By leveraging unique clinical access to patient material, we apply state-of-the-art single-cell and spatial profiling technologies alongside functional assays. This integrated approach allows us to define disease-specific immune signatures and identify novel therapeutic vulnerabilities.

A central aim of our work is to discover actionable targets within the immune compartment that can be therapeutically modulated to overcome immunosuppression and enhance treatment responses. We are particularly interested in developing and refining next-generation immunotherapeutic approaches, including cell-based strategies and immune-modulating interventions, and in exploring how these can be rationally combined with complementary technologies to improve efficacy within the central nervous system.

Through close integration of patient-derived data, experimental model systems, and clinical collaboration, we strive to translate mechanistic insights into innovative immunotherapeutic strategies that ultimately improve outcomes for patients with devastating brain diseases.